JP2019515672A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515672A5
JP2019515672A5 JP2018554677A JP2018554677A JP2019515672A5 JP 2019515672 A5 JP2019515672 A5 JP 2019515672A5 JP 2018554677 A JP2018554677 A JP 2018554677A JP 2018554677 A JP2018554677 A JP 2018554677A JP 2019515672 A5 JP2019515672 A5 JP 2019515672A5
Authority
JP
Japan
Prior art keywords
host cell
amino acid
acid sequence
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554677A
Other languages
English (en)
Japanese (ja)
Other versions
JP7198670B2 (ja
JP2019515672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028693 external-priority patent/WO2017184901A1/en
Publication of JP2019515672A publication Critical patent/JP2019515672A/ja
Publication of JP2019515672A5 publication Critical patent/JP2019515672A5/ja
Priority to JP2022139098A priority Critical patent/JP2022164858A/ja
Application granted granted Critical
Publication of JP7198670B2 publication Critical patent/JP7198670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554677A 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用 Active JP7198670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022139098A JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325428P 2016-04-20 2016-04-20
US62/325,428 2016-04-20
PCT/US2017/028693 WO2017184901A1 (en) 2016-04-20 2017-04-20 Immunomodulatory il2r fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139098A Division JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2019515672A JP2019515672A (ja) 2019-06-13
JP2019515672A5 true JP2019515672A5 (OSRAM) 2020-05-28
JP7198670B2 JP7198670B2 (ja) 2023-01-04

Family

ID=58710057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554677A Active JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用
JP2022139098A Ceased JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022139098A Ceased JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用

Country Status (7)

Country Link
US (1) US20190127435A1 (OSRAM)
EP (1) EP3445847B1 (OSRAM)
JP (2) JP7198670B2 (OSRAM)
CN (1) CN109312304A (OSRAM)
CA (1) CA3021455A1 (OSRAM)
ES (1) ES2981274T3 (OSRAM)
WO (1) WO2017184901A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196588A (en) * 2015-03-05 2023-04-19 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins and uses Thereof
WO2017201432A2 (en) * 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
JP2020511136A (ja) * 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
WO2019052562A1 (zh) * 2017-09-15 2019-03-21 科济生物医药(上海)有限公司 Il-4r的融合蛋白及其应用
CN108504685A (zh) * 2018-03-27 2018-09-07 宜明细胞生物科技有限公司 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines
MX2021015620A (es) * 2019-06-28 2022-04-18 Crage Medical Co Ltd Célula para resistir reacción al trasplante y método.
CN114945375A (zh) * 2019-09-11 2022-08-26 小利兰·斯坦福大学托管委员会 嵌合正交受体蛋白和使用方法
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
GB201913697D0 (en) * 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
CN114929752A (zh) * 2019-10-08 2022-08-19 省卫生服务机构 嵌合细胞因子受体
WO2021141986A1 (en) * 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
CN113249330A (zh) * 2021-05-20 2021-08-13 深圳市先康达生命科学有限公司 免疫细胞及其应用
CA3235607A1 (en) * 2021-11-02 2023-05-11 Soheil MESHINCHI Treatments for cancers utilizing cell-targeted therapies and associated research protocols
US12257304B2 (en) 2023-03-03 2025-03-25 Arsenal Biosciences, Inc. Systems targeting PSMA and CA9
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025085536A1 (en) * 2023-10-16 2025-04-24 Lankenau Institute For Medical Research Biologic conjugates that inhibit production of inflammatory cells and methods of use
CN117511885B (zh) * 2024-01-08 2024-06-11 青岛华赛伯曼医学细胞生物有限公司 提高识别和杀伤肿瘤能力的工程化til细胞及其应用
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5747292A (en) * 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
CN1911965B (zh) * 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
JP6578271B2 (ja) * 2013-04-17 2019-09-18 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 免疫抑制TGF−βシグナルコンバーター

Similar Documents

Publication Publication Date Title
JP2019515672A5 (OSRAM)
JP2020114264A5 (OSRAM)
JP2022113880A5 (OSRAM)
JP2020511136A5 (OSRAM)
JP2018508219A5 (OSRAM)
JP7198670B2 (ja) 免疫調整性il2r融合タンパク質およびその使用
US10822392B2 (en) Nucleic acids comprising polynucleotides encoding chimeric antigen receptors
Salter et al. Chimeric antigen receptor–modified T cells: CD19 and the road beyond
JP2021177771A5 (OSRAM)
CN108884164B (zh) 用于免疫疗法的经修饰细胞
US20200308248A1 (en) Chimeric Natural Killer Cell Receptors and Method of Using Thereof
JP2020513754A5 (OSRAM)
US11725053B2 (en) Chimeric antigen receptors comprising a human transferrin epitope sequence
JP2020517295A5 (OSRAM)
JP2018064568A (ja) Pd−l1によって誘導される免疫寛容の低減
JP2020022456A5 (OSRAM)
JP2017513478A5 (OSRAM)
CN105683214A (zh) 触发针对多种肿瘤的抗体依赖细胞毒性的嵌合受体
WO2017176525A1 (en) Car having replicated binding motifs in a co-stimulatory domain
IL255697B1 (en) Preparations and methods for programming tcr using fusion proteins
Urbanska et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
JP2021500882A5 (OSRAM)
JP2017518071A5 (OSRAM)
Wu et al. Immunotherapies: the blockade of inhibitory signals
Forsberg et al. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL